Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Jae Ho | - |
dc.contributor.author | Kim, Jeong Eun | - |
dc.contributor.author | Ahn, Jin-Hee | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Koh, Su-Jin | - |
dc.contributor.author | Cheon, Jaekyung | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Kim, Gun Min | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Sim, Sung Hoon | - |
dc.contributor.author | Park, In Hae | - |
dc.contributor.author | Kim, Sung-Bae | - |
dc.date.accessioned | 2021-12-04T03:41:18Z | - |
dc.date.available | 2021-12-04T03:41:18Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 0959-8049 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129275 | - |
dc.description.abstract | Purpose: In the randomised phase II LEO trial, we investigated the effect of adding everolimus (EVE) to letrozole (LET) in ovarian-suppressed premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) recurrent/metastatic breast cancer. Methods: Patients with progression or prior exposure to tamoxifen with or without gonadotropin-releasing hormone agonists, either sequentially or concurrently, in adjuvant or metastatic setting were randomly assigned (2 : 1) to the EVE arm (leuprorelin + LET + EVE) or the LET arm (leuprorelin + LET) until disease progression or unacceptable toxicity. The primary end-point was progression-free survival (PFS). Secondary end-points included overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Results: Between January 2014 and October 2018, 137 patients were enrolled (median age, 44 years [range, 24-56]). Of them, 75% had endocrine-sensitive disease, and 61% had visceral metastasis. With the median follow-up of 32.4 months, the median PFS was 18.1 months in the EVE arm and 13.8 months in the LET arm (HR 0.73, P = 0.137). Among patients with visceral metastases, the median PFS was significantly longer in the EVE arm (16.4 versus 9.5 months, P = 0.048). The median OS was not reached in both arms. The CBR was significantly higher in the EVE arm (83% versus 62%, P = 0.010). The ORR was similar between the two arms. The most common grade 3/4 adverse events in the EVE arm were neutropenia, alanine aminotransferase elevation and anaemia. Conclusions: EVE plus LET with ovarian-suppression resulted in longer PFS in tamoxifen-exposed HR+, HER2- metastatic breast cancer patients with visceral metastasis. (C) 2020 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.subject | PHASE-II TRIAL | - |
dc.subject | POSTMENOPAUSAL WOMEN | - |
dc.subject | AROMATASE INHIBITORS | - |
dc.subject | THERAPY | - |
dc.subject | TAMOXIFEN | - |
dc.subject | EFFICACY | - |
dc.subject | OUTCOMES | - |
dc.title | Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, In Hae | - |
dc.identifier.doi | 10.1016/j.ejca.2020.11.044 | - |
dc.identifier.scopusid | 2-s2.0-85098672640 | - |
dc.identifier.wosid | 000610215700033 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.144, pp.341 - 350 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
dc.citation.volume | 144 | - |
dc.citation.startPage | 341 | - |
dc.citation.endPage | 350 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PHASE-II TRIAL | - |
dc.subject.keywordPlus | POSTMENOPAUSAL WOMEN | - |
dc.subject.keywordPlus | AROMATASE INHIBITORS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TAMOXIFEN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Premenopausal women | - |
dc.subject.keywordAuthor | Hormone receptor-positive | - |
dc.subject.keywordAuthor | Everolimus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.